The era of sequential monotherapy is over. Trials like FLORA2 (Osimertinib + chemo) show significant progression-free and overall survival benefits, making intensified upfront treatment the new standard of care for most patients, marking a major paradigm shift in treatment.
When patients with EGFR-mutated lung cancer progress on osimertinib, a re-biopsy is essential not just for new genomic markers. It's critical for identifying histologic transformation to small cell or squamous cell cancer, which mandates a complete switch to chemotherapy-based regimens.
The COMPEL trial provides strong evidence for a "treat through progression" strategy. For patients progressing on osimertinib monotherapy, continuing the TKI while adding chemotherapy significantly reduces the probability of CNS progression, highlighting its role as a CNS protectant even when systemic efficacy is waning.
The two leading first-line combination therapies for EGFR-mutated NSCLC, FLORA2 and Mariposa, offer similar survival benefits. The decision often comes down to patient preference and managing distinct side effects: hematologic toxicity versus dermatologic issues and thromboembolic events.
When a liquid biopsy fails to detect the original EGFR driver mutation in a patient progressing on therapy, it should not be interpreted as the cancer losing its dependency. This result more likely indicates insufficient tumor DNA shedding, signaling that the test is uninformative and a tissue biopsy is needed.
For resected EGFR-mutated lung cancer, ctDNA status after surgery could personalize adjuvant osimertinib duration. A patient with initially positive ctDNA that clears on therapy is considered very high-risk for recurrence. This prompts discussion of continuing osimertinib indefinitely, beyond the standard three years.
A case study reveals the remarkable plasticity of EGFR-mutated lung cancer. After transforming from adenocarcinoma to small cell histology and receiving treatment, a subsequent biopsy showed it had reverted to adenocarcinoma. This highlights extreme tumor heterogeneity and the need for repeat biopsies upon progression.
The clinical mindset for first-line EGFR-mutated lung cancer has flipped. Instead of asking who to escalate to intensified therapy, the new paradigm starts with combination treatment as the default. The focus is now on identifying specific patients (e.g., older, frail) for whom de-escalation to monotherapy is appropriate.
For EGFR-mutated NSCLC patients with brain metastases, even numerous ones (>30), potent systemic therapy like osimertinib plus chemotherapy is often initiated first. This can achieve high rates of complete intracranial response, allowing clinicians to delay or entirely avoid whole-brain radiation and its long-term toxicities.